Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

NCT05582265 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

537

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinomas

Interventions

DRUG: Tislelizumab（neoadjuvant）
DRUG: Cisplatin （neoadjuvant）
DRUG: Nab-paclitaxel （neoadjuvant）
PROCEDURE: Surgical resection
DRUG: Cisplatin（adjuvant）
DRUG: Tislelizumab（adjuvant）
RADIATION: Radiation
DRUG: Carboplatin (neoadjuvant）
DRUG: Carboplatin (adjuvant）

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborators

[object Object]
[object Object]